Amarin to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012

Conference Call Set for 4:30 p.m. EDT on August 8th

| Source: Amarin Corporation plc

BEDMINSTER, N.J. and DUBLIN, Ireland, July 31, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2012 financial results and provide a business overview on Wednesday, August 8, 2012, at 4:30 p.m. EDT. The conference call will follow the anticipated release of Amarin's second quarter 2012 financial results earlier that day.

To participate in the call, please dial (877) 407-8033 within the United States or (201) 689-8033 from outside the United States.  A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call dial (877) 660-6853 (inside the United States) or (201) 612-7415 (outside the United States).  A replay of the call will also be available through the company's website shortly after the call. For both dial-in numbers, please use account number 286 and conference ID 398418.  The conference call can also be heard live via the investor relations section of the company's website at  

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. VascepaTM (icosapent ethyl) is Amarin's first FDA approved product. For more information about Vascepa, visit Amarin plans to separately seek approval for the use of Vascepa in the treatment of patients with high triglyceride levels who are also on statin therapy for elevated LDL-C levels, the population studied in Amarin's ANCHOR trial, after Amarin's REDUCE-IT cardiovascular outcomes trial is substantially underway. Like Amarin's MARINE study, each of Amarin's ANCHOR and REDUCE-IT studies is the subject of a Special Protocol Assessment (SPA) agreement with the FDA. For more information about Amarin, visit

The Amarin Corporation plc logo is available at

Forward-Looking Statements

This press release contains forward-looking statements, including statements about Amarin's plans to seek FDA approval for the company's product candidates, the conduct of the company's cardiovascular outcomes study, and the potential populations and indications for which the company's product candidates may be approved by the FDA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals; the risk that SPAs are not a guarantee that FDA will approve a product candidate upon submission; and the risk that historical clinical trial enrollment and randomization rates may not be predictive of future results. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Amarin's product candidates are in various stages of development and are not available for sale or use outside of approved clinical trials. This press release is intended for communication with investors. Nothing in this press release should be construed as marketing any unapproved use of such product candidates.

Investor Contact Information:
Stephen D. Schultz
Senior Director, Investor Relations
and Corporate Communications
Amarin Corporation
In U.S.: +1 (860) 572-4979 x292
Direct: 908-326-1323

Lee M. Stern
The Trout Group
In U.S.: +1 (646) 378-2922

Media contact information:
David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
In U.S.: +1 (212) 845-4271
or +1 (212) 845-4292 (office)
+1 (347) 591-8785 (mobile)